Literature DB >> 12171960

Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease.

S Schreiber1, P Rosenstiel, J Hampe, S Nikolaus, B Groessner, A Schottelius, T Kühbacher, J Hämling, U R Fölsch, D Seegert.   

Abstract

BACKGROUND: Increased expression of proinflammatory cytokines, including tumour necrosis factor alpha, interleukin 6, and interferon gamma, as well as activation of proinflammatory signalling molecules such as nuclear factor kappa B, is characteristic of inflammatory bowel disease (IBD). AIMS: To investigate expression and activation of signal transducer and activator of transcription (STAT) 1 in patients with IBD. PATIENTS: Patients with active IBD (n=42), disease specificity controls (n=8), and normal controls (n=12) were investigated.
METHODS: Expression and activation of STAT1 were assessed by western blotting and electrophoretic mobility shift assays in extracts of endoscopic colonic biopsies. Cellular localisation was determined by immunohistochemistry.
RESULTS: Western blots and immunohistochemical staining revealed an increase in STAT1 expression and activation in mucosal samples from ulcerative colitis and to a lesser extend in Crohn's disease patients. High levels of suppressor of cytokine signalling (SOCS)-3 expression, an inhibitor of STAT activation, were observed in Crohn's disease patients and normal controls in western blot experiments whereas no differences were observed for SOCS-1 expression. Phosphorylated (p) STAT1 was mainly detected in monocytic cells and neutrophils in the inflamed mucosa. Induction of remission by systemic glucocorticoids led to a decrease in levels of pSTAT1. In vitro studies indicated a direct effect of steroid treatment on STAT1 activation.
CONCLUSIONS: Expression and activation of STAT1 are predominantly heightened in ulcerative colitis and may therefore play an important role in the pathophysiology of colonic inflammation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171960      PMCID: PMC1773344          DOI: 10.1136/gut.51.3.379

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  62 in total

1.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

Authors:  S Schreiber; R N Fedorak; O H Nielsen; G Wild; C N Williams; S Nikolaus; M Jacyna; B A Lashner; A Gangl; P Rutgeerts; K Isaacs; S J van Deventer; J C Koningsberger; M Cohard; A LeBeaut; S B Hanauer
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

2.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.

Authors:  R N Fedorak; A Gangl; C O Elson; P Rutgeerts; S Schreiber; G Wild; S B Hanauer; A Kilian; M Cohard; A LeBeaut; B Feagan
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

3.  Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-kappaB activation.

Authors:  Y Wang; T R Wu; S Cai; T Welte; Y E Chin
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

4.  Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; H G Thiele; A Raedler
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

5.  Regulation of cytokine-inducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells. Role of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) and STAT1 alpha.

Authors:  K Singh; J L Balligand; T A Fischer; T W Smith; R A Kelly
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

6.  Intercellular adhesion molecule 1 (ICAM-1) is synergistically activated by TNF-alpha and IFN-gamma responsive sites.

Authors:  A Jahnke; J P Johnson
Journal:  Immunobiology       Date:  1995-07       Impact factor: 3.144

7.  Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells.

Authors:  F Powrie; M W Leach; S Mauze; S Menon; L B Caddle; R L Coffman
Journal:  Immunity       Date:  1994-10       Impact factor: 31.745

8.  Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).

Authors:  M Niessner; B A Volk
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

9.  An interferon-gamma activation sequence mediates the transcriptional regulation of the IgG Fc receptor type IC gene by interferon-gamma.

Authors:  R L Paquette; M R Minosa; M C Verma; S D Nimer; H P Koeffler
Journal:  Mol Immunol       Date:  1995-08       Impact factor: 4.407

10.  Gi2 alpha protein deficiency: a model of inflammatory bowel disease.

Authors:  U Rudolph; M J Finegold; S S Rich; G R Harriman; Y Srinivasan; P Brabet; A Bradley; L Birnbaumer
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

View more
  67 in total

Review 1.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

Authors:  James W Mandell
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

2.  Caspase recruitment domain-containing protein 8 (CARD8) negatively regulates NOD2-mediated signaling.

Authors:  Oliver von Kampen; Simone Lipinski; Andreas Till; Seamus J Martin; Wilfried Nietfeld; Hans Lehrach; Stefan Schreiber; Philip Rosenstiel
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

3.  Investigation of JAKs/STAT-3 in lipopolysaccharide-induced intestinal epithelial cells.

Authors:  L Fu; L-W Wei; M-D Zhao; J-L Zhu; S-Y Chen; X-B Jia; S-J Lai
Journal:  Clin Exp Immunol       Date:  2016-08-01       Impact factor: 4.330

Review 4.  The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications.

Authors:  Jason R Goldsmith; R Balfour Sartor
Journal:  J Gastroenterol       Date:  2014-03-21       Impact factor: 7.527

5.  Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10.

Authors:  B Lamarthée; F Malard; C Gamonet; C Bossard; M Couturier; J-C Renauld; M Mohty; P Saas; B Gaugler
Journal:  Mucosal Immunol       Date:  2015-07-08       Impact factor: 7.313

6.  Profiling CCK-mediated pancreatic growth: the dynamic genetic program and the role of STATs as potential regulators.

Authors:  Grzegorz T Gurda; Jackie Y Wang; LiLi Guo; Stephen A Ernst; John A Williams
Journal:  Physiol Genomics       Date:  2011-10-18       Impact factor: 3.107

7.  Toll-like receptor 4, F4/80 and pro-inflammatory cytokines in intestinal and mesenteric fat tissue of Crohn's disease.

Authors:  Raquel F Leal; Marciane Milanski; Maria de Lourdes S Ayrizono; Andressa Coope; Viviane S Rodrigues; Mariana Portovedo; Luiza M F Oliveira; João J Fagundes; Cláudio S R Coy; Lício A Velloso
Journal:  Int J Clin Exp Med       Date:  2013-01-26

Review 8.  Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis - NICE guidance.

Authors:  Akudo Nwaogu; Ashley Bond; Philip J Smith
Journal:  Frontline Gastroenterol       Date:  2020-06-10

9.  Role of the intracellular receptor domain of gp130 (exon 17) in human inflammatory bowel disease.

Authors:  Christoph-J Auernhammer; Kathrin Zitzmann; Fabian Schnitzler; Julia Seiderer; Peter Lohse; George Vlotides; Dieter Engelhardt; Michael Sackmann; Burkhard Goke; Thomas Ochsenkuhn
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

10.  Hyaluronan-mediated leukocyte adhesion and dextran sulfate sodium-induced colitis are attenuated in the absence of signal transducer and activator of transcription 1.

Authors:  Sudip K Bandyopadhyay; Carol A de la Motte; Sean P Kessler; Vincent C Hascall; David R Hill; Scott A Strong
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.